Altimmune (NASDAQ:ALT) Posts Earnings Results, Beats Estimates By $0.07 EPS

Altimmune (NASDAQ:ALT) released its quarterly earnings results on Wednesday. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.07, FiscalAI reports. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 47.78%.

Here are the key takeaways from Altimmune’s conference call:

• Altimmune said it raised $225 million in an oversubscribed April offering, bringing pro forma cash to about $535 million and funding the company through the expected 2029 Phase III MASH 52-week data readout.
• The company said its global Phase III MASH study, PERFORMA, is on track to start in the second half of 2026, with the protocol finalized and aligned with both the FDA and EMA.
• Management emphasized pemvidutide’s potential differentiation in MASH, pointing to a favorable tolerability profile, simple titration, sustained weight loss, and possible preservation of lean muscle mass versus some competing GLP-1-based therapies.
• Altimmune said the 48-week Phase II IMPACT results will be presented orally at EASL, including additional fibrosis analysis and other biomarker data, which the company said should reinforce interest in the program.
• Beyond MASH, Altimmune remains on track to report Phase II AUD top-line data next quarter and expects to complete enrollment in the ALD RESTORE trial in the third quarter of 2026.

Altimmune Stock Down 3.3%

Shares of NASDAQ:ALT opened at $2.92 on Friday. Altimmune has a 52-week low of $2.56 and a 52-week high of $7.73. The firm has a fifty day moving average of $3.29 and a 200 day moving average of $4.11. The firm has a market capitalization of $379.89 million, a PE ratio of -3.14 and a beta of 0.18. The company has a debt-to-equity ratio of 0.15, a quick ratio of 18.55 and a current ratio of 18.55.

Insider Transactions at Altimmune

In related news, CEO Jerome Benedict Durso bought 20,000 shares of the business’s stock in a transaction that occurred on Friday, March 6th. The stock was bought at an average cost of $3.54 per share, for a total transaction of $70,800.00. Following the completion of the transaction, the chief executive officer owned 32,500 shares of the company’s stock, valued at approximately $115,050. The trade was a 160.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its stake in Altimmune by 23.3% in the third quarter. Vanguard Group Inc. now owns 6,373,638 shares of the company’s stock worth $24,029,000 after purchasing an additional 1,206,514 shares during the last quarter. State Street Corp raised its stake in shares of Altimmune by 42.2% during the fourth quarter. State Street Corp now owns 5,119,703 shares of the company’s stock valued at $18,482,000 after acquiring an additional 1,518,448 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Altimmune by 13.6% during the fourth quarter. Geode Capital Management LLC now owns 2,292,410 shares of the company’s stock valued at $8,278,000 after acquiring an additional 275,025 shares during the last quarter. Two Sigma Investments LP raised its stake in shares of Altimmune by 356.6% during the third quarter. Two Sigma Investments LP now owns 1,996,848 shares of the company’s stock valued at $7,528,000 after acquiring an additional 1,559,562 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in shares of Altimmune by 140.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,349,293 shares of the company’s stock valued at $4,871,000 after acquiring an additional 787,036 shares during the last quarter. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently commented on ALT shares. Truist Financial started coverage on shares of Altimmune in a research report on Wednesday, March 18th. They set a “buy” rating and a $12.00 price target for the company. Citizens Jmp reduced their price target on shares of Altimmune from $14.00 to $11.00 and set a “market outperform” rating for the company in a research report on Thursday. Wall Street Zen lowered shares of Altimmune from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. HC Wainwright boosted their price target on shares of Altimmune from $12.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, March 16th. Finally, Barclays began coverage on shares of Altimmune in a research report on Tuesday, January 27th. They set an “overweight” rating and a $20.00 price target for the company. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $17.50.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.